 |
BioWorld-International-2003-07-23
Antisense Approach To Muscular Dystrophy Shows Early Promise
Zeltia Rallies Support For Yondelis In Attempt To Secure EU Approval
It's crunch time this week for Spanish firm Zeltia SA. Since late last month, the Madrid-based company has been engaged in an unusually vocal lobbying campaign on behalf of its cancer drug Yondelis, which the London-based European Medicines Evaluation Agency is currently evaluating. (BioWorld International)